炎症性肠病中的致病共生菌:起源、潜在机制及临床意义
综述探讨炎症性肠病(IBD)中致病共生菌的特征与临床意义,涉及克罗恩病(CD)和溃疡性结肠炎(UC)相关细菌与真菌,讨论其与临床特征(如爬行脂肪、伤口愈合受损、粪便蛋白水解活性增高)的关联及潜在机制,并审视其对当前IBD治疗的影响及早期开发中的靶向新方法。
要点
- IBD患者肠道内存在具致病特性的致病共生菌,包括细菌和真菌。
- 黏附侵袭性大肠杆菌在CD中的作用已被关注,新研究识别出更多致病共生菌。
- 靶向致病共生菌的新方法尚处早期开发阶段,需更多研究明确其作用方式。
核心结论
- 致病共生菌可能参与IBD发病,但需更多工作明确其作用方式,确定其与特定疾病特征间的因果关系或可改善患者诊疗。
研究设计与样本
- 综述,探讨IBD中致病共生菌的起源、相关临床特征、潜在机制及对治疗的影响。
主要发现
- CD患者中与爬行脂肪相关的致病共生菌为无害梭菌(Clostridium innocuum)。
- CD患者中与伤口愈合受损相关的致病共生菌为汉森德巴利酵母(Debaryomyces hansenii)。
- UC严重程度的生物标志物粪便蛋白水解活性增高与普通拟杆菌(Bacteroides vulgatus)相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需更多工作明确致病共生菌的作用方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gut microbiota plays a significant role in the pathogenesis of both forms of inflammatory bowel disease (IBD), namely, Crohn's disease (CD) and ulcerative colitis (UC). Although evidence suggests dysbiosis and loss of beneficial microbial species can exacerbate IBD, many new studies have identified microbes with pathogenic qualities, termed "pathobionts," within the intestines of patients with IBD. The concept of pathobionts initiating or driving the chronicity of IBD has largely focused on the putative aggravating role that adherent invasive Escherichia coli may play in CD. However, recent studies have identified additional bacterial and fungal pathobionts in patients with CD and UC. This review will highlight the characteristics of these pathobionts and their implications for IBD treatment. Beyond exploring the origins of pathobionts, we discuss those associated with specific clinical features and the potential mechanisms involved, such as creeping fat (Clostridium innocuum) and impaired wound healing (Debaryomyces hansenii) in patients with CD as well as the increased fecal proteolytic activity (Bacteroides vulgatus) seen as a biomarker for UC severity. Finally, we examine the potential impact of pathobionts on current IBD therapies, and several new approaches to target pathobionts currently in the early stages of development. Despite recognizing that pathobionts likely contribute to the pathogenesis of IBD, more work is needed to define their modes of action. Determining whether causal relationships exist between pathobionts and specific disease characteristics could pave the way for improved care for patients, particularly for those not responding to current IBD therapies.
引用
- Gilliland A, Chan JJ, De Wolfe TJ, et al. Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care. Gastroenterology. 2023. PMID: 37734419. doi:10.1053/j.gastro.2023.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。